APGE stock forecast, quote, news & analysis
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications... Show more
Why Apogee Therapeutics (APGE) Is Up +36% in the Last 30 Days
Key Takeaways
- APGE stock surged +36% over the past 30 days, driven primarily by positive Phase 2 clinical data for its lead candidate zumilokibart (APG777) and a successful $403 million public offering.
- Over the past quarter, shares rose +12%, reflecting a volatile path with an early dip followed by a strong rebound on pipeline progress.
- Key catalysts include sustained 52-week efficacy data in atopic dermatitis (AD), positioning APG777 for potentially longer dosing intervals versus competitors.
- Analyst enthusiasm, with price target increases, and robust cash raise bolstered investor confidence amid biotech sector volatility.
- Market sentiment shifted positively on clinical milestones, outweighing minor insider selling.
Apogee Therapeutics (APGE) Company Overview and Market Position
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology (I&I) indications, including atopic dermatitis (a chronic skin condition), asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. Its lead asset, zumilokibart (APG777), is a subcutaneous (under the skin) extended half-life monoclonal antibody (mAb, lab-produced protein mimicking immune response) targeting IL-13, currently in Phase 2 trials for moderate-to-severe AD. The company also advances other candidates like APG279 and APG273 in early stages.
Apogee competes in the crowded I&I space against giants like Regeneron (REGN) but differentiates through potential for less frequent dosing (every 3-6 months). Strong fundamentals, including a $6.8 billion market cap and beta of 1.02 (indicating market-like volatility), support resilience, with recent cash infusion extending runway for trials. This pipeline exposure explains the stock's sensitivity to clinical updates.
Apogee Therapeutics (APGE) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, APGE stock climbed +36%, from approximately $67 to $91. The movement was volatile and trend-driven, with a sharp surge in the latter half following key announcements, reaching new 52-week highs near $91 amid elevated volumes.
In the past quarter, shares advanced +12%, from around $81. Performance was range-bound early with a dip to the mid-$60s, then recovered strongly, reflecting broader biotech momentum and company-specific catalysts. Overall, the stock exhibited upward bias despite fluctuations.
What Drove APGE Stock Price in the Last 30 Days
The primary driver was the release of positive 52-week Phase 2 Part A data for APG777, demonstrating maintenance and deepening of skin clearance responses in AD patients on every 3- and 6-month dosing. This positioned the asset as potentially best-in-class, sparking a 20%+ rally and analyst upgrades, including from Mizuho and Wedbush.
Compounding this, Apogee announced a $300 million public offering, upsized and priced at $70 per share for $350 million, closing at $403 million with underwriters' option exercise. Tied to the data readout, the raise signaled confidence and extended cash runway, propelling shares up 17.8% post-announcement.
Positive market sentiment in biotech, analyst price target hikes to $110+, and competition narrative versus established AD therapies further fueled the uptrend, offsetting minor CEO insider selling of 20,000 shares.
What Drove APGE Stock Performance Over the Last Quarter
The quarter's +12% gain stemmed from cumulative clinical progress outweighing early pressures. An initial dip reflected broader sector rotation and a terminated collaboration, but rebound gained traction on sustained trial momentum.
Macro factors like stabilizing interest rates aided biotech funding environment, while institutional interest grew on APG777's differentiated profile. Analyst buy ratings persisted, with targets implying significant upside. The late-quarter data and offering provided the strongest lift, countering volatility from I&I peers and reinforcing competitive positioning in high-demand AD market.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from hundreds available, each analyzing thousands of tickers across strategies like trend-following, mean reversion, and momentum. These curated bots highlight those with superior recent performance metrics, including win rates, profit factors, and risk-adjusted returns over various timeframes from intraday to long-term. Traders can filter by asset class, volatility, or specific sectors like biotech, gaining insights into algorithmic edges. Whether for swing trading APGE-like movers or diversified portfolios, the section offers actionable, data-backed options. Explore the trending performers to enhance your stock analysis and potentially automate market trends.
APGE Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming Phase 2 topline data readouts for APG777 in AD, expansion into asthma and eosinophilic esophagitis trials, and use of proceeds from the recent offering for accelerated development.
Key industry trends include AD market growth and competition from incumbents. Macro conditions like biotech funding access and interest rates remain influential. Strategic developments such as partnerships or regulatory milestones (e.g., FDA interactions) could sway sentiment. Risks involve trial setbacks, dilution, or sector-wide selloffs; catalysts include additional data or analyst updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
APGE's Indicator enters downward trend
The Aroon Indicator for APGE entered a downward trend on June 02, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 96 similar instances where the Aroon Indicator formed such a pattern. In of the 96 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 36 cases where APGE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on June 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on APGE as a result. In of 45 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APGE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
APGE broke above its upper Bollinger Band on June 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for APGE just turned positive on June 03, 2026. Looking at past instances where APGE's MACD turned positive, the stock continued to rise in of 23 cases over the following month. The odds of a continued upward trend are .
APGE moved above its 50-day moving average on June 11, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for APGE crossed bullishly above the 50-day moving average on June 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APGE advanced for three days, in of 175 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.426) is normal, around the industry mean (20.059). P/E Ratio (0.000) is within average values for comparable stocks, (35.871). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). APGE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (361.315).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. APGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology